Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.82 | 1.93 |
NAV | ₹503.24 | ₹38.02 |
Fund Started | 10 May 2004 | 12 Nov 2018 |
Fund Size | ₹8080.97 Cr | ₹3018.76 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit load of 0.50% if redeemed within 1 month. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 19.08% | 18.02% |
3 Year | 20.09% | 20.16% |
5 Year | 22.60% | 24.51% |
1 Year
3 Year
5 Year
Equity | 99.48% | 98.63% |
Cash | 0.52% | 1.37% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.43% |
Divi's Laboratories Ltd. | 9.28% |
Lupin Ltd. | 7.27% |
Cipla Ltd. | 5.71% |
Apollo Hospitals Enterprise Ltd. | 5.31% |
Dr. Reddy's Laboratories Ltd. | 5.19% |
Glaxosmithkline Pharmaceuticals Ltd. | 3.61% |
Vijaya Diagnostic Centre Ltd. | 3.53% |
Abbott India Ltd. | 3.46% |
Medplus Health Services Ltd. | 3.41% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 10.78% |
Suven Pharmaceuticals Ltd. | 9.49% |
Cipla Ltd. | 8.55% |
Ipca Laboratories Ltd. | 7.98% |
Globus Medical Inc | 5.58% |
Gland Pharma Ltd. | 4.86% |
Laurus Labs Ltd. | 4.51% |
Alembic Pharmaceuticals Ltd. | 4.38% |
Apollo Hospitals Enterprise Ltd. | 4.27% |
Sai Life Sciences Ltd. | 4.03% |
Name | Akshay Sharma | Jay Kothari |
Start Date | 01 Dec 2022 | 16 Mar 2018 |
Name
Start Date
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. |
Launch Date | 10 May 2004 | 12 Nov 2018 |
Description
Launch Date